GHRP-2 vs Ipamorelin
Research Verdict
Ipamorelin is the stronger research reference for the stated comparison criteria. GHRP-2: stronger GH release per dose in comparative studies.
Quick Answers
Which is better, GHRP-2 or Ipamorelin?
Ipamorelin is the stronger research reference for the stated comparison criteria. GHRP-2: stronger GH release per dose in comparative studies.
What is the key difference between GHRP-2 and Ipamorelin?
Ipamorelin is defined by its selectivity - it releases GH without affecting cortisol, prolactin, or LH; GHRP-2 produces more GH but with some cortisol co-release. The selectivity vs. potency tradeoff is the central distinction.
Evidence Comparison
GHRP-2: stronger GH release per dose in comparative studies. Ipamorelin: Phase 2 post-operative ileus data (Helsinn), demonstrated selectivity - no effect on cortisol, prolactin, or LH at GH-stimulating doses. Ipamorelin has the better formal clinical trial infrastructure; GHRP-2 has the stronger GH dose-response.
Evidence Context Favoring GHRP-2
Maximal GH stimulation research where cortisol co-release is an acceptable tradeoff.
Evidence Context Favoring Ipamorelin
GH research requiring hormonal selectivity - no cortisol, prolactin, or LH perturbation - which is ipamorelin's defining advantage.
Side-by-Side Snapshot
| Evidence grade | GHRP-2: Level C Ipamorelin: Level B |
|---|---|
| Research status | GHRP-2: Preclinical Ipamorelin: Phase 2 |
| Primary category | GHRP-2: Growth Hormone Ipamorelin: Growth Hormone |
| Cited studies | GHRP-2: 2 Ipamorelin: 3 |